US Bankruptcy Chapter 11 Insolvency SEC Filings — June 23, 2026
The June 23, 2026 bankruptcy/insolvency landscape is dominated by two distinctly structured restructurings: a completed Chapter 11 emergence (Office Properties Income Trust) and a new Chapter 11 filing with asset sales (Sangamo Therapeutics). OPIRQ's emergence involves complex tax gearing—massive cancellation of debt (COD) income offsetting NOLs and creating a NUBIL—which could pressure REIT qualification and future distributable income. Sangamo's filing triggers a stalking horse sale of core assets to Eli Lilly and Astellas for $75M+ in upfront/milestone payments, coupled with a $30M DIP facility, implying an imminent liquidation/run-off. Both filings reveal a sector theme of resource-constrained companies monetizing tax attributes (OPIRQ) or intellectual property (Sangamo) to satisfy creditors, with material insider trading signals notably absent, suggesting management teams are already disengaged or locked up post-restructuring. The combined period-over-period data is sparse due to the event-driven nature, but the forward-looking guidance hints at constrained operations for OPIRQ and a wind-down for Sangamo.